A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.
Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.
Cancer Center at Illinois member Jeff Chan, associate professor of chemistry, recently published research demonstrating the development of an activatable cancer therapeutic to help eliminate the side effects of traditional chemotherapies.
In a pilot study, a telephone-based dietary intervention designed to improve bowel function was shown to be widely acceptable to participants who had had surgery for rectal cancer.
In a policy statement, the American Society of Clinical Oncology calls for global equity in clinical trials.
The International Agency for Research on Cancer published a report titled “Maternal Orphans due to Cancer: The intergenerational impact of cancer deaths in women,” summarizing the findings from previous publications by researchers from IARC and partners that dealt with the theme of the intergenerational impact of cancer deaths in women.
An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.
University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan have identified a protein that helps prevent metastasis of HER2-positive breast cancer. About 20% of breast cancer patients are HER2-positive, and these cancers tend to be more aggressive than other types.
A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.
